lifestyle.celebhomes.net
Home
Sample Page
Author:
SOLIGENIX, INC.
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
April 28, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
April 2, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
March 31, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet’s Disease
March 26, 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
March 23, 2026
Soligenix Announces HyBryte™ Clinical Summary Published in “Expert Opinion on Investigational Drugs”
March 19, 2026
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
March 10, 2026
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
November 21, 2025